4. årlige ECD Medical Symposium Paris, Frankrike

Xavier Solanich, MD, PHD
Boulevard de l'Hôpita
Paris, Frankrike
1. april 2016

Gruppebilde fra medisinsk symposium i Paris 2016

Sammendrag av symposiet

Erdheim-Chester Disease Global Alliance er glad for å kunne presentere følgende sammendrag av foredragene som ble holdt på årets 4. internasjonale medisinske ECD-symposium, avholdt 15. september 2016 på Hôpital Pitié-Salpêtrière i Paris, Frankrike. Møtet ga medisinske fagpersoner mulighet til å samarbeide om ECD-forskning, dele medisinske funn og diskutere pasientbehandling. Takk til årets medvert, professor Julien Haroche, MD, PhD; til alle foredragsholdere som delte sine data og sin ekspertise under paneldiskusjonene; til alle deltakere som var interessert i å lære mer om ECD; og til alle som var involvert i planleggingen og gjennomføringen av dette arrangementet. En spesiell takk til frivillige som utarbeidet dette sammendraget for fellesskapet og for fagpersonene som ikke hadde mulighet til å delta.

Programmer med agenda for symposiet

Presentasjoner

Følgende presentasjoner ble holdt på møtet i 2016. Besøk ECD Global Alliance YouTube-kanal for alle publiserte ECD-relaterte videoer.

PresenterPresentation SlidesVideos
Corrado Campochiaro, MDManagement of ECD Symptoms and Side Effects of TreatmentsManagement of ECD Symptoms and Side Effects of Treatments
Giulio Cavalli, MDAdult Onset (Infratentorial) Leukoencephalopathy as Presenting Manifestation of Erdheim-Chester DiseaseAdult Onset (Infratentorial) Leukoencephalopathy as Presenting Manifestation of Erdheim-Chester Disease
Carine Courtillot, MDEndocrine manifestations in Erdheim-Chester diseaseEndocrine manifestations in Erdheim-Chester disease
Benjamin Durham, MDInsights into the Cell-of-Origin of the Histiocytoses Using Patient-Derived Xenograft Murine ModelsInsights into the Cell-of-Origin of the Histiocytoses Using Patient-Derived Xenograft Murine Models
Marina Ferrarini, MDTailoring Treatment for Erdheim-Chester Disease: Focus on ECDTailoring Treatment for Erdheim-Chester Disease: Focus on ECD
Ronald Go, MDEfficacy of Cladribine (2-CdA) in the Treatment of Erdheim-Chester Disease (ECD)Efficacy of Cladribine (2-CdA) in the Treatment of Erdheim-Chester Disease (ECD)
Filip Janku, MD, PhDEncouraging activity of MEK inhibitor trametinib in patients with Erdheim-Chester disease irrespective of BRAF mutation statusClinical Molecular Profiling to Detect Targetable Alterations in Archival Tumor Tissue and Cell-free DNA from Patients with Erdheim-Chester DiseaseEncouraging activity of MEK inhibitor trametinib in patients with Erdheim-Chester disease irrespective of BRAF mutation statusClinical Molecular Profiling to Detect Targetable Alterations in Archival Tumor Tissue and Cell-free DNA from Patients with Erdheim-Chester Disease
Javier Martin, MD, PhDFuture Genetic Studies in Erdheim-Chester disease – GWAS StudyFuture Genetic Studies in Erdheim-Chester disease – GWAS Study
Kenneth McClain, MD, PhDElevated CSF Osteopontin and Circulating Cells with BRAF Mutations in Patients with Langerhans Cell Histiocytosis-Associated Neurodegeneration -A Model for ECD?Elevated CSF Osteopontin and Circulating Cells with BRAF Mutations in Patients with Langerhans Cell Histiocytosis-Associated Neurodegeneration -A Model for ECD?
Augusto Vaglio, MD, PhDMRI evidence of cardiac involvement in Erdheim-Chester diseaseMRI evidence of cardiac involvement in Erdheim-Chester disease